Evra 203 + 33.9 ug/24h №3 transdermal system

Active ingredient

Evra - transdermal therapeutic system (TTC):

1 system contains norelgestromin (NG) 6 mg, ethinyl estradiol (EE) 600 mcg; in a bag from the combined material of 1 piece, in a transparent bag from a polymeric film 3 bags; in a pack of cardboard 1 or 3 bags of plastic film (containing 3 or 9 TTS), along with special calendar stickers to mark the period of use.

Mechanism of action

Contraceptive agent for transdermal use. Evra inhibits the pituitary gonadotropic function, inhibits follicle development and interferes with the process of ovulation. Evra's contraceptive effect is enhanced by increasing the viscosity of the cervical mucus and reducing the susceptibility of the endometrium to the blastocyte. Pearl Index - 0.90.

Contraception in women.

Dosage and administration

To achieve the maximum contraceptive effect, women should use Evra TTC in strict accordance with the instructions. Only one TTC Evra can be used at a time.

TTC Evra should be glued on clean, dry, intact and healthy skin of the buttocks, abdomen, outer surface of the upper part of the shoulder or upper part of the body with minimal hair growth, in areas where it will not come into contact with tight clothing.

Adverse reactions

From the central and peripheral nervous system: dizziness, migraine, paresthesias, hypostezia, convulsions, tremor, emotional lability, depression, anxiety, insomnia, drowsiness.

Cardiovascular: increased blood pressure, palpitations, edematous syndrome, varicose veins.

On the part of the digestive system: gingivitis, anorexia or increased appetite, gastritis, gastroenteritis, dyspepsia, abdominal pain, vomiting, diarrhea, flatulence, constipation, hemorrhoids.

On the part of the respiratory system: upper respiratory tract infection, shortness of breath, asthma.

Reproductive system: pain during sexual intercourse (dyspareunia), vaginitis, dysmenorrhea, decreased libido, increased mammary glands, menstrual disorders (including intermenstrual bleeding, hypermenorrhea), changes in vaginal secretion, changes in cervical mucus, lactation that occurs out of connection with childbirth, ovarian dysfunction, mastitis, breast fibroadenomas, ovarian cysts.

On the part of the urinary system: urinary tract infections.

On the part of the musculoskeletal system: muscle cramps, myalgia, arthralgia, ostalgia (including back pain, pain in the lower extremities), tendiosis (tendon changes), muscle weakness.

On the part of the skin and its appendages: pruritus, urticaria, skin rash, contact dermatitis, bullous rash, acne, discoloration of the skin, eczema, increased sweating, alopecia, photosensitization, dry skin.

Contraindications

hypersensitivity to the components of Evra;

venous thrombosis, incl. a history of deep vein thrombosis, pulmonary thromboembolism;

arterial thrombosis, including a history of acute cerebrovascular accident, myocardial infarction, retinal artery thrombosis, or precursors of thrombosis (including angina pectoris or transient ischemic attack);

the presence of serious or multiple risk factors for arterial thrombosis (severe arterial hypertension - BP more than 160/100 mm Hg. Art.; diabetes mellitus with vascular lesion; hereditary dyslipoproteinemia);

genetic predisposition to venous or arterial thrombosis, such as resistance of activated protein C, deficiency of antithrombin-III, deficiency of protein C, deficiency of protein S, hyperhomocysteinemia and the presence of antiphospholipid antibodies (antibodies against cardiolipin, lupus anticoagulant);

migraine with aura;

confirmed or suspected breast cancer;

endometrial cancer and confirmed or suspected estrogen-dependent tumors;

liver adenoma and carcinoma;

genital bleeding;

postmenopausal period;

age up to 18 years;

postpartum period (4 weeks);

lactation period;

use on the area of ​​the mammary glands, as well as on hyperemic, irritated or damaged skin

Special notes

There is no clinical evidence that the transdermal contraceptive system is safer than oral contraceptives in any aspect.

Before starting or resuming the use of TTC Evra, a detailed medical history (including family history) must be collected and pregnancy should be excluded. It is necessary to measure blood pressure and conduct a physical examination, taking into account contraindications and warnings.

Storage conditions

The drug should be stored out of the reach of children at a temperature not higher than 25 ° C. Shelf life - 3 years.